Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes by Jensen, D H et al.
ARTICLE
Steroid-induced insulin resistance and impaired glucose
tolerance are both associated with a progressive decline
of incretin effect in first-degree relatives of patients
with type 2 diabetes
D. H. Jensen & K. Aaboe & J. E. Henriksen & A. Vølund &
J. J. Holst & S. Madsbad & T. Krarup
Received: 11 August 2011 /Accepted: 28 December 2011 /Published online: 29 January 2012
# Springer-Verlag 2012
Abstract
Aims/hypothesis The aim of this study was to evaluate the
separate impact of insulin resistance and impaired glucose
tolerance (IGT) on the incretin effect.
Methods Twenty-one healthy glucose-tolerant first-degree
relatives of patients with type 2 diabetes underwent a 75 g
OGTT, an isoglycaemic i.v. glucose test and a mixed meal to
evaluate the incretin effect before and after treatment with
dexamethasone to increase insulin resistance. Beta cell glu-
cose sensitivity, beta cell index and fasting proinsulin were
measured as indices of beta cell function.
Results After dexamethasone, ten individuals had increased
insulin resistance but normal glucose tolerance (NGT), while
11 individuals with an equal increase in insulin resistance
developed IGT. In the NGT and IGT groups, the incretin
effects were 71±3.2% and 67±4.6% (p00.4) before treat-
ment, but decreased significantly in both groups to 58±5.2%
and 32±8.8% (p<0.05 between groups) after treatment. Dexa-
methasone increased total glucagon-like peptide-1 and
glucose-dependent insulinotropic peptide responses to the
OGTT. The impaired incretin effect in NGT was observed in
the absence of reductions in beta cell glucose sensitivity and
beta cell index during i.v. glucose, corrected for insulin resis-
tance, but in parallel with increased proinsulin/C-peptide ratio.
Conclusion/interpretation Insulin resistance and IGT, repre-
senting two stages in the path towards diabetes, are associ-
ated with differential reductions in the incretin effect seen
before the development of IGT and overt type 2 diabetes.
The reduction is unrelated to secretion of incretin hormones,
but is related to insulin resistance and subtle beta cell
defects, and is further aggravated on development of IGT.
Trial registration: ClinicalTrials.gov NCT00784745.
Funding: This study was supported by a grant from the
Novo Nordisk Foundation.
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Introduction
‘The incretin effect’ is the phenomenon that oral glucose
elicits a greater insulin response compared with glucose
infused intravenously, giving identical plasma glucose pro-
files (isoglycaemia) [1]. It is mediated by two incretin hor-
mones, glucagon-like peptide 1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP) [2–4].
The incretin effect is markedly reduced in type 2 diabetes
[5, 6], and is diminished in individuals with impaired glu-
cose tolerance (IGT) [7] and obesity [8]. The loss of the
incretin effect is associated with a reduced insulinotropic
effect of GLP-1 [9, 10] and an almost complete loss of late-
phase insulin secretion in response to GIP [10]. The incretin
effect is also reduced in diabetes secondary to chronic
pancreatitis [11], suggesting that the impairment is second-
ary to the development of diabetes [11] and raising the
question of when the defect becomes apparent. Prediabetes
is characterised by insulin resistance [12], and if secretion of
insulin is insufficient to compensate for this, the result is
IGT or frank diabetes [12].
We examined whether the incretin effect would be affected
by induction of insulin resistance and/or development of IGT
in healthy individuals. We used dexamethasone as an exper-
imental tool to mimic the insulin resistance and glucose intol-
erance seen in prediabetes. In a previous study [13], short-
term dexamethasone resulted in increased insulin resistance in
healthy relatives of individuals with type 2 diabetes; in addi-
tion, some participants developed glucose intolerance. By
increasing insulin resistance to the same degree in all partic-
ipants while inducing glucose intolerance in only some indi-
viduals, we aimed to isolate the individual impact of these two
factors on the incretin effect. We examined first-degree rela-
tives of individuals with type 2 diabetes and measured the
incretin effect before and after dexamethasone [5, 14].
We also investigated whether a reduction in the incretin
effect is associated with beta cell defects. The insulin re-
sponse to i.v. glucose is impaired and proinsulin processing
is defective in the early stages of development of type 2
diabetes [15, 16]. Therefore, we evaluated beta cell function
during the i.v. glucose test, and calculated the proinsulin/C-
peptide ratio in the fasting state as an index of beta cell
dysfunction [16]. Normally, during changes in insulin sen-
sitivity the beta cells respond with proportionate reciprocal
changes in insulin secretion, thereby maintaining normal
glucose tolerance (NGT) [17, 18]. Therefore, insulin
secretion should be evaluated in relation to insulin resistance
[19], to detect subtle beta cell defects [20]. Finally, all
participants underwent a mixed meal before and after dexa-
methasone in order to examine beta cell function and incre-
tin hormone secretion during physiological stimulation.
Methods
Participants Eleven men and ten women with at least one
first-degree and one second-degree relative with type 2 diabetes
underwent a 75 g OGTT to ensure NGT according to WHO
criteria [21, 22]. After dexamethasone, the OGTT showed that
one group retained NGT (n010), while the other developed
IGT (n011). There were no significant differences in baseline
characteristics between the groups (Table 1). All participants
gave oral and written consent. The study was approved by
Scientific Ethics Committee D of the Capital Region
of Denmark (registration number H-D-2008-087), and
followed the principles of the Helsinki Declaration II (regis-
tered with Clinicaltrials.gov, registration no. NCT00784745).
Experimental design Within 7 days of the start of dexameth-
asone, participants were studied on three different days with
OGTT, i.v. glucose and a meal. The same three tests were
performed on the three consecutive days immediately follow-
ing 5 days of dexamethasone, 2 mg twice daily. On days 1 and
2 after the 5 days of dexamethasone, 2 mg dexamethasone
was given in the afternoon. All participants were studied after
an overnight (10 h) fast. On experimental days, with partic-
ipants in the recumbent position, an i.v. catheter was inserted
into an antebrachial vein and the armwas wrapped in a heating
blanket in order to arterialise blood samples. [23]. The con-
tralateral arm was cannulated for glucose infusion (20% [wt/
vol.]). All participants ingested 75 g of water-free glucose
dissolved in 300 ml water. Blood samples were collected as
indicated in Figs 1 and 2.
Table 1 Anthropometric data at baseline for patients who retained
NGT or developed IGT after treatment with dexamethasone
Characteristic NGT IGT
n (women/men) 4/6 5/6
Age (years) 27±2.4 29±2.4
BMI (kg/m2) 23±1.0 25±0.9
FPG (mmol/l) 5.0±0.07 5.1±0.12
PG120 (mmol/l) 6.2±0.20 6.4±0.22
Matsuda index 8.4±1.2 6.2±0.90
There were no significant differences between groups
Matsuda index was calculated from the OGTT
PG120, plasma glucose at 120 min during the 75 g OGTT
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The plasma glucose (PG) curves from the OGTT were
copied by i.v. infusion of 20% glucose, guided by frequent
measurements of PG. On a separate day, a mixed meal
(200 ml low-fat milk, 50 g white bread, 50 g rye bread,
10 g butter, 40 g cheese and 20 g jam [34% fat, 47%
carbohydrate, 19% protein; a total of 2,370 kJ]) was
ingested within 15 min. The sequence of OGTT and test
meal was randomised. Blood samples were drawn as indi-
cated in Figs 3 and 4.
Blood samples PG was measured at the bedside from blood
sampled in fluoride-containing tubes, and immediately
centrifuged for 1 min at 7,400g at room temperature. Blood
for the measurement of GLP-1, GIP and glucagon was
distributed into chilled tubes containing EDTA, which were
immediately placed on ice and subsequently centrifuged at
4°C for 15 min at 1,200g. Plasma was stored at −20°C, with
the exception of plasma for insulin and C-peptide, which
was stored at −80°C.
Analyses PG concentrations were measured by the glucose
oxidase method, using a glucose analyser (2300 Stat Plus
analyser; YSI, Yellow Springs, OH, USA). Plasma samples
were assayed for total GLP-1 as previously described [24],
using a radioimmunoassay with antiserum specific for the
C-terminal of the GLP-1 molecule (antiserum 89390, pro-
duced in house), which therefore reacts equally with intact
GLP-1 and the primary (N-terminally truncated) metabolite.
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Fig. 1 Results during the 75 g OGTT and the isoglycaemic i.v. glucose
infusion. a–d PG: (a) NGT before dexamethasone; (b) IGT before
dexamethasone; (c) NGT after dexamethasone; and (d) IGT after
dexamethasone. e–h Plasma insulin: (e) NGT before dexamethasone;
(f) IGT before dexamethasone; (g) NGT after dexamethasone; and (h)
IGT after dexamethasone. i–l Plasma C-peptide: (i) NGT before
dexamethasone; (j) IGT before dexamethasone; (k) NGT after dexa-
methasone; and (l) IGT after dexamethasone. m–p ISR: (m) NGT
before dexamethasone; (n) IGT before dexamethasone; (o) NGT after
dexamethasone; and (p) IGT after dexamethasone. Black circles, dur-
ing the 75 g OGTT; white circles, during isoglycaemic i.v. glucose
infusion
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Total GIP was measured using the C-terminally directed
antiserum R65, produced in house [25, 26], which reacts
fully with intact GIP and the N-terminally truncated metab-
olite. The glucagon assay is directed against the C-terminal
(antibody 4305, produced in house) and measures glucagon
of mainly pancreatic origin [27–29]. Plasma insulin and C-
peptide were measured using the Autodelphia automatic
fluoroimmunoassay (Wallac, Turku, Finland). Proinsulin
was analysed using a two-site enzyme-linked immunoad-
sorbent assay based on two monoclonal antibodies [30].
Calculations and statistical analysis All results are expressed
as mean±SEM. AUCs were calculated using the trapezoidal
rule and are presented as total or incremental values (base-
line values subtracted), as indicated. Incretin effects were
calculated by the following formula: 100×(incremental [i]
AUC) during OGTT–iAUC during i.v. glucose infusion)/
iAUC during OGTT. Insulin secretion rate (ISR) was calcu-
lated by deconvolution of plasma C-peptide and application
of population-based variables for C-peptide kinetics [31].
ISR is expressed as pmol kg−1 min−1. Insulin resistance was
estimated by the Matsuda index, which is calculated using
only values obtained from the OGTT [32].
We estimated beta cell glucose sensitivity based on the
relationship between ISR and glucose levels during the three
tests. The calculated ISR was plotted against PG to establish
the dose–response relationship (beta cell glucose sensitivity)
for each individual on each experimental day, and the slopes of
these linear relations during the upstroke phase of the insulin
response were expressed as pmol kg−1 min−1 (mmol/l)−1 [9].
We used this variable to estimate the potentiating effect of the
incretin hormones, i.e. a measure of the dynamic ‘incretin
effect’, by calculating the ratio of beta cell glucose sensitivity
during the OGTT to the i.v. glucose infusion. In addition, we
calculated the ‘beta cell index’, i.e. the ratio of iAUCISR to
iAUCGlucose during the 240 min (iAUCISR/iAUCGlucose). Beta
cell function was related to insulin resistance by calcu-
lation of the disposition index (DI[Glucose sensitivity]) i.e.
beta cell glucose sensitivity×Matsuda index and the disposi-
tion index (DI[Beta cell index]), i.e. (iAUCinsulin/iAUCglucose)×
Matsuda index), assuming the existence of an inverse hyper-
bolic relationship between insulin secretion and action. To
evaluate this, we performed weighted least-squares linear
regression analysis [33] with log beta cell glucose sensitivity
as the dependent and log Matsuda index as the inde-
pendent variable, and also between log iAUCISR/iAUCGlucose
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Fig. 2 Results during the 75 g OGTT and the isoglycaemic i.v. glucose
infusion. a–d Total GLP-1: (a) NGT before dexamethasone; (b) IGT
before dexamethasone; (c) NGT after dexamethasone; and (d) IGT
after dexamethasone. e–h Total GIP: (e) NGT before dexamethasone;
(f) IGT before dexamethasone; (g) NGT after dexamethasone; and (h)
IGT after dexamethasone. i–l Glucagon: (i) NGT before dexametha-
sone; (j) IGT before dexamethasone; (k) NGT after dexamethasone;
and (l) IGT after dexamethasone. Black circles, during the 75 g OGTT;
white circles, during isoglycaemic i.v. glucose infusion
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and log Matsuda index for all the participants during i.v.
glucose before and after dexamethasone. Ideally, the
slope of this relationship should be −1.0. For DI(Glucose sensitivity)
the slope of the regression line before dexamethasone
was −0.45 (95% CI −0.54, −0.044; r200.24, p<0.05),
and for DI(Beta cell index) −0.72 (95% CI −1.51, −0.47;
r200.44, p<0.05) justifying the calculation of the two
DI values. After dexamethasone, the slope of the line
for DI(Glucose sensitivity) was −0.48 (95% CI −0.64, −0.14;
r200.30, p<0.05) and for DI(Beta cell index) −0.61 (95%
CI −0.78, −0.25; r200.40, p<0.05).
Wilcoxon’s test was used for within-group differences
and Mann–Whitney U test for between-group differences
because of the non-normal distribution of the data. Our
power calculation before undertaking the study (power of
80%) indicated that a 25% change in incretin effect required
eight participants to achieve statistical significance at the 5%
level (two-sided paired t test). However, because of the non-
normal distribution, the less powerful Wilcoxon test had to
be used, but the approximate 20% decrease in incretin effect
in the NGT group reached statistical significance. Linear
regression analysis was performed using standard methods.
A p value<0.05 was considered statistically significant.
Results
Glucose Fasting PG (FPG) concentrations were similar on
all three experimental days before and after dexamethasone
in the two groups. Dexamethasone increased FPG in both
the NGT (5.0±0.06 vs 5.3±0.12 mmol/l, p<0.05) and IGT
(5.1±0.07 vs 5.7±0.10 mmol/l) groups (p<0.05 for the
increase in FPG in both groups); p<0.05 for the difference
between the two groups after treatment.
The glucose curves on the OGTT and i.v. glucose
infusion days were similar (isoglycaemia) before and
after dexamethasone (Fig. 1a–d). AUC during the
OGTT and i.v. glucose infusion increased significantly
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Fig. 3 Results before and after treatment with dexamethasone during
the mixed meal for: (a, b) PG; (c, d) plasma insulin; (e, f) plasma C-
peptide; and (g, h) ISR. Results are shown for the NGT (a, c, e, g) and
IGT (b, d, f, h) groups. Black circles, before treatment; white circles,
after treatment
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Fig. 4 Results before and after treatment with dexamethasone during
the mixed meal for: (a, b) total GLP-1; (c, d) total GIP; and (e, f)
glucagon. Results are shown for the NGT (a, c, e,) and IGT (b, d, f)
groups. Black circles, before treatment; white circles, after treatment
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in both groups after treatment (p<0.05), and during the
mixed meal in IGT (Table 2). There were no significant
differences between groups before dexamethasone dur-
ing any of the tests. However, after dexamethasone, the
AUC increased significantly in the IGT compared with
the NGT group in all tests (p<0.05). The iAUC in-
creased significantly in both groups during OGTT and
the i.v. glucose infusion. There were no differences in
iAUC between the groups for any test. That a difference
was found between groups using total AUC and not
iAUC is related to the differences in FPG values.
The total amounts of glucose infused in NGT vs IGT
were 28.1±2.2 vs 36.0±2.2 g (p<0.05) before and 44.2±3.0
vs 64.1±3.9 g after (p<0.05) dexamethasone.
Total GLP-1 Plasma GLP-1 levels are presented in Figs 2 a–
d and 4a–d. There were no baseline differences before (NGT
30±3.8 vs IGT 27±2.6 pmol/l) or after (NGT 27±1.7 vs
IGT 29±1.0 pmol/l) dexamethasone. There were no signif-
icant differences between groups regarding AUCs of any of
the tests before or after treatment with dexamethasone. The
AUCs increased numerically in both groups during all three
Table 2 AUC and iAUC values
for glucose, GLP-1, GIP and
glucagon in response to an oral
glucose load (75 g), the isogly-
caemic i.v. glucose infusion and
a mixed meal before and after
dexamethasone
The AUC and iAUC values rep-
resent the total and incremental
areas during the 240 min tests
*Significant difference between
groups (p<0.05)
†Significant differences between
OGTT and i.v. glucose infusion
within groups (p<0.05)
‡Significant differences within
groups before compared with
after treatment (p<0.05)
Variable Before After
NGT group IGT group NGT group IGT group
n (women/men) 4/6 5/6 4/6 5/6
AUC
Glucose (mol/l×min)
OGTT 1.4±0.05 1.5±0.03 1.6±0.05*,‡ 2.0±0.1*,‡
i.v. glucose infusion 1.5±0.04 1.5±0.03 1.6±0.05*,‡ 2.0±0.1*,‡
Mixed meal 1.3±0.03 1.4±0.02 1.4±0.05* 1.6±0.04*,‡
Total GLP-1 (nmol/l×min)
OGTT 6.5±0.5† 6.4±0.6† 7.2±0.5†,‡ 7.1±0.6†,‡
i.v. glucose infusion 4.4±0.3 4.2±0.3 5.2±0.3 4.8±0.2‡
Mixed meal 6.4±0.3 6.7±0.5 6.9±0.8 7.3±0.64
Total GIP (nmol/l×min)
OGTT 9.3±0.7† 9.9±1.0† 12.7±1.5†,‡ 13.2±1.3†,‡
i.v. glucose infusion 1.5±0.2 1.5±0.2 2.1±0.3‡ 2.8±0.6‡
Mixed meal 21.7±1.8 17.3±2.1 24.3±2.3‡ 23.1±1.8‡
Glucagon (nmol/l×min)
OGTT 1.1±0.2 1.2±0.1 1.6±0.4 1.8±0.2‡
i.v. glucose infusion 1.1±0.2 1.2±0.2 1.6±0.4‡ 1.6±0.2‡
Mixed meal 1.9±0.3 2.4±0.2 2.7±0.5‡ 3.1±0.3‡
iAUC
Glucose (mol/l×min)
OGTT 0.24±0.04 0.31±0.05 0.36±0.04*,‡ 0.56±0.8*,‡
i.v. glucose infusion 0.26±0.04 0.31±0.05 0.32±0.04*,‡ 0.57±0.09*,‡
Mixed meal 0.18±0.03 0.16±0.02 0.19±0.02 0.23±0.04
Total GLP-1 (nmol/l×min)
OGTT 0.72±0.4† 0.62±0.71† 1.0±0.6† 1.0±0.7†
i.v. glucose infusion −2.1±0.5 −1.2±0.3 −1.5±0.3 −1.4±0.5
Mixed meal −17±2.5 −17±1.5 0.33±0.4 −0.27±0.6
Total GIP (nmol/l×min)
OGTT 7.2±0.8† 7.3±1.0† 9.6±1.1†,‡ 7.7±1.9†
i.v. glucose infusion −0.47±0.2 −0.36±0.2 −1.1±0.4 −2.1±0.9
Mixed meal 18±2.1 14±2.1 21±2.6‡ 13±2.9
Glucagon (nmol/l×min)
OGTT −0.8±0.2 −0.9±0.1 −1.3±0.2‡ −1.3±0.2†,‡
i.v. glucose infusion −0.7±0.1 −1.2±0.1 −1.2±0.3*,‡ −1.8±0.2*,‡
Mixed meal −0.2±0.2 −0.2±0.2 −0.3±0.1 −0.6±0.2
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tests after dexamethasone, and significantly in IGT during
OGTT and the i.v. glucose infusion and during OGTT in
NGT (p<0.05; Table 2). The iAUC did not change signifi-
cantly in either group in any test after dexamethasone, and
there were no significant differences between groups in any
tests before or after dexamethasone. The differences ob-
served between incremental and total values are related to
the increase seen in fasting GLP-1.
Total GIP There were no baseline differences in fasting GIP
between the three experimental days in the two groups,
either before or after dexamethasone (Figs 2 e–h and 4e–h).
Within each group, there was a highly significant increase in
fasting values from 9.1±1.0 to 14±1.2 pmol/l (p<0.001) in
the NGT group and from 11±1.1 to 29±5.5 pmol/l after
dexamethasone (p<0.001) in the IGT group.
There were no significant differences in total AUC or
iAUC between groups in any of the tests (Table 2). The
AUCs increased significantly in both groups in all three
tests after dexamethasone whereas iAUCs only increased
significantly in the NGT group during the OGTT and
the mixed meal.
Insulin, C-peptide and ISR Fasting insulin, C-peptide and
ISR values did not differ between groups on the three
experimental days before dexamethasone (Figs 1e–h and
i–l and 3e–h and i–j). All three variables increased in both
groups after treatment (p<0.05), but to a greater extent in
the IGT group compared with the NGT group (p<0.05).
The iAUC for insulin, C-peptide and ISR were greater in
both groups during OGTT compared with i.v. glucose infu-
sion both before and after dexamethasone (p<0.05; Table 3).
The iAUCs increased two- to threefold after dexamethasone
in both groups during oral and i.v. glucose (p<0.05), but did
not differ significantly between the two groups (Table 3).
During the mixed meal, the insulin, C-peptide and ISR
responses increased significantly in both groups after dexa-
methasone, but the responses were similar in the two groups
both before and after dexamethasone (Table 3).
Incretin effects The incretin effect, calculated from insulin
iAUC, was 71±3.2% and 67±4.6% before (p00.4) and 58±
5.2% and 32±8.8% after treatment (p<0.05), in the NGT
and IGT groups, respectively (Table 3). In both groups, the
incretin effect was reduced after dexamethasone (p<0.05).
The incretin effect, calculated from C-peptide or ISR, was
smaller compared with that calculated from insulin, but with
concordant changes (Table 3). The dynamic ‘incretin effect’
estimated by beta cell glucose sensitivity during oral and i.v.
glucose was 2.6±0.33 (NGT) and 2.1±0.31 (IGT) (p00.3)
before, and decreased to 1.6±0.22 and 1.4±0.10 (p00.057),
respectively, after dexamethasone. The decrease was signifi-
cant in both groups (p<0.05).
Matsuda index The Matsuda index before treatment was
8.4±1.2 (NGT) and 6.2±0.90 (IGT) (p00.12). After dexa-
methasone, the Matsuda index decreased significantly in
both groups (p<0.05) to 3.6±0.62 and 2.6±0.19, respec-
tively (p00.14). The decrease in Matsuda index did not
differ between groups (p00.3)
Proinsulin/C-peptide ratio The proinsulin/C-peptide ratios
were similar at baseline, but increased after dexamethasone
from 1.4±0.14 to 2.3±0.30 (p<0.05) in the NGT group and
from 1.7±0.18 to 3.9±0.56 (p<0.05) in the IGT group,
being significantly higher in IGT than in NGT (p<0.05).
Indices of beta cell function during i.v. glucose The beta cell
glucose sensitivity to i.v. glucose was similar in the two
groups before dexamethasone, and increased by approxi-
mately 100% in NGT and 40% in IGT after dexamethasone
(p<0.05; Table 3). DI(Glucose sensitivity) to i.v. glucose did not
differ between the groups before dexamethasone. After
treatment DI(Glucose sensitivity) decreased significantly in both
groups, and was significantly more reduced in the IGT
group compared with the NGT group (p<0.05; Table 3).
The beta cell index increased numerically in both groups
after dexamethasone, but only significantly in the NGT
group. It was similar in the two groups before but signifi-
cantly smaller in IGT compared with NGT after dexameth-
asone (Table 3). DI(Beta cell index) did not differ between the
groups before dexamethasone. DI(Beta cell index) decreased
significantly in IGT after dexamethasone and was signifi-
cantly smaller compared with NGT (p<0.05; Table 3).
Indices of beta cell function during OGTT The beta cell
glucose sensitivity during OGTT (Table 3) illustrates the
potentiating effect of the incretin hormones when compared
with beta cell glucose sensitivity during i.v. glucose. The
beta cell glucose sensitivity during OGTT did not differ
before dexamethasone. After treatment, beta cell glucose
sensitivity increased significantly in the NGT group, while
the absence of an increase in the IGT group is in accordance
with the severely reduced incretin effect (Table 3). The
DI(Glucose sensitivity) during OGTT was significantly lower in
the IGT group before and decreased significantly in both
groups after dexamethasone, and was significantly lower in
the IGT group compared with the NGT group after dexa-
methasone (Table 3).
The beta cell index was similar during OGTT in the two
groups before, but significantly lower in IGT compared with
NGT after dexamethasone (Table 3). The DI(Beta cell index)
during OGTT did not differ between the groups before
treatment. After treatment, a significant reduction was
observed in both groups, with a significantly lower
DI(Beta cell index) in the IGT group compared with the NGT
group (Table 3).
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Indices of beta cell function during mixed meal During the
mixed meal, the beta cell glucose sensitivity and beta cell
index did not differ significantly between groups before and
after dexamethasone (Table 3). The DI(Glucose sensitivity) was
numerically reduced in both groups after dexamethasone but
only significantly in the IGT group, and was significantly
lower in IGT compared with NGT (p<0.05, Table 3). DI(Beta
cell index) decreased significantly only in IGT after dexameth-
asone, and was significantly lower after treatment in IGT
compared with NGT (Table 3). When comparing the mixed
meal and OGTT, the DI(Glucose sensitivity) was greater during
the mixed meal in both groups both before and after dexa-
methasone (p<0.05, Table 3). DI(Beta cell index) was also
numerically greater when comparing the OGTT and mixed
meal, but this failed to reach statistical significance, except
for IGT after dexamethasone (Table 3).
Glucagon Fasting plasma glucagon increased significantly in
both groups after treatment (NGT, from 8.1±0.54 to 12.3±
1.04 pmol/l; IGT, from 9.6±0.66 to 14.0±0.91 pmol/l) (p<
0.05) (Figs 2i–l and 4i–l), with no difference between groups.
The AUC and iAUC did not differ between groups during any
test before treatment (Table 3). After dexamethasone, the
iAUC decrement after OGTT and i.v. glucose increased in
both NGT and IGT (Table 3). The suppression of glucagon
was slightly but insignificantly delayed during the first 45 min
Table 3 Incremental beta cell
secretory responses (insulin, C-
peptide, ISR) to oral glucose and
i.v. isoglycaemic glucose infu-
sion, incretin effects in the NGT
and IGT groups before and after
dexamethasone, and indices of
beta cell function
The iAUCs were calculated us-
ing the total duration of the tests
from 0 to 240 min
*Significant differences between
OGTT and i.v. glucose infusion
within groups (p<0.05)
†Significant differences within
groups after compared with be-
fore treatment (p<0.05)
‡Significant difference between
groups (p<0.05)
Group Before dexamethasone After dexamethasone
NGT IGT NGT IGT
n (women/men) 4/6 5/6 4/6 5/6
Insulin (nmol/l×min)
OGTT 27±3.5* 33±3.6* 86±17.6*,† 80±10.0*,†
i.v. glucose infusion 8.5±1.9 11±2.1 35±7.6† 51±8.0†
Mixed meal 30±6.8 23±2.6 55±8.8† 60±7.2†
C-peptide (nmol/l×min)
OGTT 264±22* 288±25* 533±66*,† 456±49*,†
i.v. glucose infusion 119±18 146±15 286±29† 366±28†
Mixed meal 248±29 198±14 393±41† 342±36†
ISR (nmol kg−1 min−1)
OGTT 1.0±0.09* 1.0±0.1* 2.0±0.3*,† 1.7±0.2*,†
i.v. glucose infusion 0.4±0.06 0.5±0.07 1.0±0.1† 1.3±0.1†
Mixed meal 1.0±0.1 0.8±0.08 1.5±0.1† 1.2±0.2†
Incretin effect (%)
Insulin 71±3.2 67±4.6 58±5.2†,‡ 32±8.8†,‡
C-peptide 56±4.0 49±3.8 40±7.9†,‡ 13±8.0†,‡
ISR 55±4.1 49±4.0 41±7.1‡ 13±7.7†,‡
Beta cell glucose sensitivity (nmol kg−1 min−1 mmol/l−1)
OGTT 2.8±0.31* 1.9±0.14* 3.4±0.42*,†,‡ 1.9±0.36 ‡
i.v. glucose infusion 1.0±0.12 1.0±0.07 2.1±0.20† 1.4±0.23†
Mixed meal 4.2±0.61 2.8±0.27 6.2±0.98 3.7±0.47
DI(Glucose sensitivity) (nmol kg
−1 min−1 mmol/l−1)
OGTT 23±3.7*,‡ 14±2.3*,‡ 12±2.2*,†,‡ 5.6±0.76†,‡
i.v. glucose infusion 8.8±0.94 6.7±0.92 7.3±1.2‡ 4.2±0.47†,‡
Mixed meal 34±6.8 20±4.0 21±4.1‡ 11±1.2†,‡
Beta cell index (nmol kg−1 min−1 mmol/l−1)
OGTT 4.5±0.67* 4.2±0.88* 8.8±1.4*,†,‡ 3.4±0.60*,‡
i.v. glucose infusion 1.7±0.21 1.9±0.27 3.9±0.48†,‡ 2.6±0.3‡
Mixed meal 4.9±0.64 5.2±0.53 8.8±1.1† 6.7±1.3
DI(Beta cell index) (nmol kg
−1 min−1 mmol/l−1)
OGTT 37±6.4* 27±8.0* 29±6.1*,†,‡ 8.4±1.4*,†,‡
i.v. glucose infusion 14±1.6 12±2.5 14±2.9‡ 6.2±0.7†,‡
Mixed meal 41±8.5 32±5.3 30±5.1 17±2.8†,‡
Diabetologia (2012) 55:1406–1416 1413
during oral compared with i.v. glucose in the NGT group,
while in the IGT group the glucagon suppression was signif-
icantly greater during i.v. glucose compared with OGTT (p<
0.05). This was mainly due to a significant (p<0.05) delay in
glucagon suppression during the first 120 min during OGTT
(Fig. 2k–l). The AUC increased significantly in all tests except
in the NGT group during OGTT, which probably represents a
type II error. The AUC during the mixed meal increased
significantly in both groups, with no significant differences
between groups in any tests using AUC.
Discussion
In the current study, we confirm that the incretin effect is
intact in healthy first-degree relatives of type 2 diabetes
patients, amounting to approximately 70%, as previously
observed [34]. However, the incretin effect was reduced
when insulin resistance increased, even while normal glu-
cose tolerance was maintained. When our participants de-
veloped glucose intolerance in addition to insulin resistance,
we observed a further, significant, decline in the incretin
effect. As the increase in insulin resistance in the two groups
was identical, our results suggest that insulin resistance and
glucose intolerance contribute as separate factors to the
reduced incretin effect in patients with type 2 diabetes. Even
though our study design per se does not allow us to con-
clude that the reduced incretin effect observed is a conse-
quence and not a cause of the declining glucose tolerance,
previous studies [11, 35] from our group have addressed this
question, and together the evidence supports the former.
The mechanistic explanation for the impaired incretin
effect in our study does not involve a reduced secretion of
the two incretin hormones GLP-1 and GIP (measured as
total hormones to capture all changes in secretion, indepen-
dent of possible variations in dipeptidyl peptidase-4 (DPP-
4) activity [36]) as neither GLP-1 nor GIP secretion de-
creased during OGTT after dexamethasone. Therefore, the
present results indicate that the decline in the incretin effect
is due to a loss of the insulinotropic properties of the two
incretin hormones, which is most pronounced in the IGT
group. A previous study in a population without genetic
disposition to type 2 diabetes similarly found that steroid
treatment did not change the overall secretion of GLP-1 but
led to an increase in overall secretion of GIP and glucagon
during a mixed meal [37].
Insulin resistance induced with 5 days of dexamethasone
was based on previous studies [13], which, in agreement
with the present study, showed that some individuals treated
with dexamethasone developed IGT while the others
remained NGT. On the three consecutive test days immedi-
ately after the 5 days of dexamethasone the fasting concen-
trations of glucose and insulin did not increase or decrease
from day 1 to 3, suggesting that a steady state, with regard to
insulin resistance, had been reached.
In addition to reduced insulin-mediated peripheral glu-
cose disposal [38, 39], glucocorticoids are also known to
reduce oxidative and non-oxidative pathways of glucose
disposal [38], reduce muscle glycogen synthase activity
[40], and to induce hepatic insulin resistance [39]. As such,
the insulin resistance induced by glucocorticoids resembles
the insulin resistance seen in type 2 diabetes. The NGT
group did show a small increase in FPG and AUCGlucose
after dexamethasone, but this increase was small indicating
that the beta cell could compensate adequately for the in-
creasing insulin resistance.
As beta cell function is a determinant of normal or
abnormal glucose tolerance, we calculated indices of beta
cell function. The proinsulin/C-peptide ratio is a sensitive
index of beta cell dysfunction, and has been reported to
predict the risk of type 2 diabetes in individuals with NGT
[41], increasing progressively as beta cell function decreases
and glycaemia increases [42]. The proinsulin/C-peptide ra-
tio increased after dexamethasone in both groups, but more
marked in the IGT group. The increase in the ratio may
reflect the increased demand for insulin, forcing the beta cell
to secrete immature granules with a high content of proin-
sulin, as previous reported by Kahn et al [43].
The insulin response to i.v. glucose is impaired early in
the development of type 2 diabetes, and is one of the factors
determining the progression from normal to abnormal glu-
cose tolerance [44]. Beta cell glucose sensitivity is an inte-
grated measure of glucose-induced insulin secretion over
hours, and was significantly impaired in the IGT group,
with an approximately 40% decrease after dexamethasone
when corrected for insulin resistance by calculation of
the DI(Glucose sensitivity); the decrease was numerically
lower in the NGT group, and failed to reach statistical
significance. The third index we calculated, DI(Beta cell index),
decreased significantly in the IGT group. Taken together, the
results indicate that the reduced incretin effect is an early
phenomenon in the development of type 2 diabetes, which
is, in part, due to a general beta cell dysfunction. It was
observed in people with preserved NGT, and in whom the
proinsulin/C-peptide ratio was significantly increased, and the
DI(Beta cell index) and DI(Glucose sensitivity) were not significantly
reduced. Along with the progressive impairment in the incre-
tin effect in the group developing IGT, parallel statistically
significant reductions in DI(Glucose sensitivity) and DI(Beta cell index)
were observed, indicating a more severe global beta cell
dysfunction.
The beta cell glucose sensitivity to oral glucose was
greater in both groups compared with i.v. glucose before
dexamethasone, and in the NGT group after dexamethasone,
in accordance with the potentiation of insulin secretion by
the incretin hormones. In the participants with IGT, the beta
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cell glucose sensitivity did not differ significantly during the
i.v. glucose and OGTT, in accordance with the severe im-
pairment of the incretin effect in this group after dexameth-
asone. Interestingly, during the mixed meal, where insulin
secretion is stimulated not only by the incretin hormones but
also by non-glucose substrates and neurotransmitters, the
beta cell glucose sensitivity and the beta cell index were
numerically greater compared with oral glucose, except for
the beta cell index in NGT after dexamethasone, which was
similar. This indicates a greater potentiation of glucose-
induced insulin release by mixed-meal stimulation than by
OGTT, where primarily the incretin hormones and glucose
stimulate insulin release.
Recently, it has been argued [45] that the maximal secre-
tory capacity of the beta cells is reached during the IVGTT of
isoglycaemic challenges for the study of incretin effect in type
2 diabetes, meaning that the incretin hormones cannot further
increase insulin secretion on oral stimulation, which could
explain the apparent loss of the incretin effect. However, in
our participants with NGT, this is unlikely to be the cause of
the reduced incretin effect, particularly as the beta cell
response to the mixed meal was significantly greater
than to i.v. glucose after glucocorticoid treatment. In addition,
other studies showed that supraphysiological concentrations
of GLP-1 dramatically increased glucose-induced insulin
secretion in type 2 diabetes [10, 46].
Regarding glucagon, we found that the increase in insulin
resistance was associated with an inappropriate large in-
crease in glucagon secretion. This is of interest because an
increase in glucagon secretion is an important diabetogenic
factor in type 2 diabetes. Alpha cell dysfunction must there-
fore be included among the diabetogenic effects of gluco-
corticoids. Furthermore, the increase in both groups point to
alpha cell dysfunction as a very early sign in diabetes
development. A delayed glucagon suppression during
OGTT, as seen here in the IGT group after dexamethasone,
has also been observed in type 2 diabetes [47].
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